1. FDA approves Sarepta’s DMD drug that it had previously rejected — Biogen chalks up another failure — The House passes the Lower Drug Costs Now Act, but it’s unlikely to become law — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Pain Pumps

Discussion in 'Kimberly-Clark' started by Anonymous, Oct 21, 2013 at 4:03 PM.

  1. Anonymous

    Anonymous Guest

    What can we do to slow down the on slot of EXPAREL?
     
  2. Anonymous

    Anonymous Guest

    Take two asprins and call me tomorrow!
     
  3. Anonymous

    Anonymous Guest

    It is having a big impact in my area. Hard to defend against an injection that works. Anyone having any luck selling against it?
     
  4. Anonymous

    Anonymous Guest

    Exparel is killing pain pumps period!!! Not much to say but start interviewing
     
  5. Anonymous

    Anonymous Guest

    Start interviewing!
     
  6. Anonymous

    Anonymous Guest

    Meh, too early to throw in the towel to Exparel... http://www.eurekalert.org/pub_releases/2013-10/wkh-bit102813.php

    One thing is certain, the days of hospitals paying huge $ for disposable devices with highly variable (if any) reimbursement are behind us. Continuous nerve blocks are quickly evolving, which is a great thing. We can either evolve with the advancements or keep plodding along in the same direction, which isn't working out well for most this year.
     
  7. Anonymous

    Anonymous Guest

    You need to throw in the towel!!! It's over for you my friend!
     
  8. Anonymous

    Anonymous Guest

    Get out of bed and go sell something
     
  9. Anonymous

    Anonymous Guest

    We have yesterdays old technology at todays inflated prices with nothing new on the horizon. Evenly we will be cut back like supplies.
     
  10. Anonymous

    Anonymous Guest

    No need to Exparel sells itself, only reason I get out of bed is to cash my large checks from it selling itself
     
  11. Anonymous

    Anonymous Guest

    Pffft. Enjoy it while it lasts mr. Big Time! A SS of Bupiv+Decadron just as effective as your snake oil and costs a fraction of the price. Encapsulate my balls with your mouth.
     
  12. Anonymous

    Anonymous Guest

    Heading to the bank again this morning!
     
  13. Anonymous

    Anonymous Guest

    I just had 3 customers in my area start using it lat Tuesday and they all Said Exparel work very well.
     
  14. Anonymous

    Anonymous Guest

    Does anyone have a contact at Pacira, I need to apply?
     
  15. Anonymous

    Anonymous Guest

    As a clinician I hope you are sharing this information with your surgeons. I am happy for your success however different modalities offer surgeons options. Why is it so hard to work together and ensure the patient has the best outcome always?

    8.2 Adverse Reactions Reported in All Wound Infiltration Clinical Studies

    Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

    The safety of bupivacaine liposome suspension was evaluated in 10 randomized, double-blind, local administration into the surgical site clinical studies involving 823 patients undergoing various surgical procedures. Patients were administered a dose ranging from 66 to 532 mg of bupivacaine liposome suspension. In these studies, the most common adverse reactions (incidence greater than or equal to 10%) following bupivacaine liposome suspension administration were nausea, constipation, and vomiting.

    The common adverse reactions (incidence greater than or equal to 2% to less than 10%) following bupivacaine liposome suspension administration were pyrexia, dizziness, edema peripheral, anemia, hypotension, pruritus, tachycardia, headache, insomnia, anemia postoperative, muscle spasms, hemorrhagic anemia, back pain, somnolence, and procedural pain.

    The less common/rare adverse reactions (incidence less than 2%) following bupivacaine liposome suspension administration were chills, erythema, bradycardia, anxiety, urinary retention, pain, edema, tremor, dizziness postural, paresthesia, syncope, incision site edema, procedural hypertension, procedural hypotension, procedural nausea, muscular weakness, neck pain, pruritus generalized, rash pruritic, hyperhidrosis, cold sweat, urticaria, bradycardia, palpitations, sinus bradycardia, supraventricular extrasystoles, ventricular extrasystoles, ventricular tachycardia, hypertension, pallor, anxiety, confusional state, depression, agitation, restlessness, hypoxia, laryngospasm, apnea, respiratory depression, respiratory failure, body temperature increased, blood pressure increased, blood pressure decreased, oxygen saturation decreased, urinary retention, urinary incontinence, vision blurred, tinnitus, drug hypersensitivity, and hypersensitivity.

    Neurological and Cardiac Adverse Reactions Reported in All Wound Infiltration Clinical Studies

    In the bupivacaine liposome suspension wound infiltration studies, adverse reactions with an incidence greater than or equal to 1% in the Nervous System Disorders system organ class following bupivacaine liposome suspension administration were dizziness (6.2%), headache (3.8%), somnolence (2.1%), hypoesthesia (1.5%), and lethargy (1.3%). The adverse reactions with an incidence greater than or equal to 1% in the Cardiac Disorders system organ class following bupivacaine liposome suspension administration were tachycardia (3.9%) and bradycardia (1.6%).
     
  16. Anonymous

    Anonymous Guest

    One word for you On-Q reps out there….EXPAREL
     
  17. Anonymous

    Anonymous Guest

    Great post! Thanks for your insight
     
  18. Anonymous

    Anonymous Guest

    you must be from SA or Austin. You should run. We're kicking your asses and going to continue to do so. Have a good day.
     
  19. Anonymous

    Anonymous Guest

    it is so nice selling an injectable that is having such positive results for patients. How is your territory doing? Not going up in sales that is for sure! Exparel
     
  20. Anonymous

    Anonymous Guest

    Fixed your post, you pharma puppet. Glad I sold my stock at $58. The end is near